Infectious disease An orphan drug for treating life-threatening infections–eg, meningococcemia–aka meningococcal septicemia, gram-negative bacteria, and N meningitidis infection in Pts with partial hepatectomy. See Meningococcemia.
References in periodicals archive ?
Neuprex, a bactericidal permeability increasing protein, fights bacterial poisoning, but was developed for adults and older children.
They also will see whether they are able to discontinue blood-pressure medications and ventilators earlier by using Neuprex.
San Francisco, CA) on the Xanelim antibody for psoriasis (Phase III) and other indications; with Baxter Healthcare Corporation to develop NEUPREX (rBPI-21) for Crohn's disease (Phase II) and other indications; with Millennium on two biotherapeutic agents, CAB-2 and LDP-01, for certain vascular inflammation indications (preclinical); and with Onyx Pharmaceuticals, Inc.
The new drug, Neuprex, wraps itself round the poisons which are spread in the bloodstream, and neutralises them.
Dr Parvis Habibi runs the paediatric intensive care unit at London's St Mary's Hospital where 100 children took part in the Neuprex trial.
On January 9, 2007 the company initiated a phase I/II trial with Neuprex on allogenic stem cell transplant patients.
Neuprex and other BPI products are also under consideration for use in the treatment of gram-negative sepsis, acute and chronic focal infections and as adjunct therapy with conventional antibiotics.
Neuprex is currently in Phase I studies and multiple Phase II trials will begin this fall.
We have previously shown the efficacy of our Neuprex product in eleven reproducible, statistically significant animal studies.
Completion of three sets of Neuprex(TM) Phase I clinical trials, in the United States and Europe: XOMA's Neuprex product is a recombinant DNA-derived fragment of natural, human bactericidal/permeability increasing protein (rBPI).
XOMA scientists also identified three functional domains of Neuprex that are responsible for the known properties of the molecule.
and XOMA's bactericidal/permeability-increasing protein (BPI), including NEUPREX for product commercialization in conjunction with an exclusive licensing agreement with Zephyr Sciences, Inc.